Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth/Aviron FluMist

Executive Summary

Nasal influenza vaccine will be reviewed by Vaccines & Related Biological Products Advisory Committee during July 26-27 meeting. The companies are seeking an indication for use in healthy children and adults. "We are hopeful about getting on the market this year, but obviously that requires FDA approval, and I think especially today, it's difficult to make firm projections about when this vaccine will be approved," AHP Chief Operating Officer Robert Essner said during an April 25 conference call. FluMist BLA was submitted Oct. 30

You may also be interested in...



Wyeth-Ayerst/Aviron Flumist

Vaccines & Related Biological Products Advisory Committee will meet to discuss nasal influenza vaccine Flumist on July 26-27. The committee will discuss Flumist's safety and efficacy data on the first day of the meeting and the product's proposed indications on the second day. The meeting begins at 10:15 a.m. on July 26 and at 8:30 a.m. on July 27 and will be held at the Holiday Inn in Gaithersburg, Md. Wyeth told investors in April it expected the committee to review the product in July (1"The Pink Sheet" April 30, In Brief)

Wyeth-Ayerst/Aviron Flumist

Vaccines & Related Biological Products Advisory Committee will meet to discuss nasal influenza vaccine Flumist on July 26-27. The committee will discuss Flumist's safety and efficacy data on the first day of the meeting and the product's proposed indications on the second day. The meeting begins at 10:15 a.m. on July 26 and at 8:30 a.m. on July 27 and will be held at the Holiday Inn in Gaithersburg, Md. Wyeth told investors in April it expected the committee to review the product in July (1"The Pink Sheet" April 30, In Brief)

Wyeth/Aviron FluMist Full Launch Will Come Ahead Of 2002-2003 Flu Season

Wyeth-Lederle/Aviron's FluMist intranasal influenza vaccine will be fully launched at the beginning of the 2002-2003 flu season after an initial rollout in late 2001, Wyeth Vaccines Chief Scientific Officer George Siber, MD, told analysts.

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel